Parallax Volatility Advisers
SVA

Parallax Volatility Advisers’s Sinovac Biotech, Ltd SVA Stock Holding History

Parallax Volatility Advisers’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-36,200
Closed -$251K – 4662
2018
Q4 		$251K Buy
+36,200
New +$264K ﹤0.01% 1684

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parallax Volatility Advisers's SVA Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Sinovac Biotech, Ltd (SVA) in Q3 2019, closing a stake of 5,055 shares — an estimated $33K sold.

Parallax Volatility Advisers first reported a position in SVA in Q4 2018 and held it in 3 quarters. The position peaked at $43K in Q4 2018. 23 funds tracked by Wall St. Rank hold SVA as of Q3 2019.

  • Parallax Volatility Advisers reported no remaining Sinovac Biotech, Ltd position as of Q3 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,055 Sinovac Biotech, Ltd shares in Q3 2019, an estimated $33K.
  • Parallax Volatility Advisers first reported a position in Sinovac Biotech, Ltd in Q4 2018 and held it in 3 quarters.
  • Parallax Volatility Advisers's Sinovac Biotech, Ltd position peaked at $43K in Q4 2018.
  • 23 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.